SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) — Journey Medical Corporation (‘Journey Medical’ or the ‘Company’) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on the marketing and sale of U.S. Food and Drug Administration (‘FDA’)-approved prescription pharmaceutical products for dermatological conditions, has announced that it will release its year-end 2025 financial results following the closure of U.S. financial markets on Wednesday, March 25, 2026.
Management at Journey Medical will host a conference call and audio webcast on the same day at 4:30 p.m. ET. To participate in the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). Callers are encouraged to connect approximately 10 minutes before the scheduled start time and request to join the Journey Medical conference call. For those wishing to register, please navigate to this link. Registered participants will receive their dial-in number upon registration.
Additionally, a live audio webcast of the conference call will be accessible on the News and Events page within the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will be available for replay for approximately 30 days following the event.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) is a commercial-stage pharmaceutical entity that primarily focuses on the marketing and sale of FDA-approved prescription products for dermatological conditions. The Company utilises an effective sales and marketing model to promote a portfolio of eight branded prescription drugs designed to treat and heal common skin ailments.
The team at Journey Medical comprises industry experts with substantial experience in developing and commercialising some of the most successful prescription brands in dermatology. Headquartered in Scottsdale, Arizona, Journey Medical was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). The Company’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (‘SEC’). For further information about Journey Medical, please visit www.journeymedicalcorp.com.
Contact Information
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
Source: Journey Medical Corporation 2026 GlobeNewswire, Inc., source Press Releases